Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00072410 · ClinicalTrials.gov registry record · Phase 1
Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer
A Phase 1 study, sponsored by Ludwig Institute for Cancer Research.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT00072410 is a Phase 1 study that has completed, run by Ludwig Institute for Cancer Research. The registered enrollment target is 7 participants.
The verdict
NCT00072410, a Phase 1 study, has completed, sponsored by Ludwig Institute for Cancer Research.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells. Giving radiolabeled monoclonal antibody directly into the abdominal cavity may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of giving radiolabeled monoclonal antibody therapy directly into the abdominal cavity in treating patients who have advanced ovarian epithelial cancer.
Interventions
- BIOLOGICAL 90Y-hu3S193
- BIOLOGICAL 111In-hu3S193
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2003-11 |
| Est. Completion | 2006-11-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00072410
The ClinicalTrials.gov registry entry for NCT00072410 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ludwig Institute for Cancer Research, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 90Y-hu3S193 is the first listed.
NCT00072410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00072410 about?
NCT00072410 is a clinical study titled "Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer". RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells. Giving radiolabeled monoclonal antibody directly into the abdominal cavity may kill more tumor cells. PURPOSE: Phase I trial to study the effec...
What is the current status of trial NCT00072410?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2003-11. Estimated completion is 2006-11-15.
What interventions are being tested in trial NCT00072410?
The interventions under investigation include: 90Y-hu3S193 (BIOLOGICAL), 111In-hu3S193 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00072410?
This trial is sponsored by Ludwig Institute for Cancer Research, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.